

Clinical Trial Protocol

Iranian Registry of Clinical Trials

28 May 2026

Evaluation of the effect of traditional Persian diabetes product (Tabashir tablet) on blood glucose level in patients with type 2 diabetes: a double-blind placebo-controlled clinical trial

Protocol summary

Study aim

Determining the effectiveness of the traditional medicinal product, diabetes pills (Qoras Tabashir), in comparison with standard treatment in controlling blood sugar in patients with type 2 diabetes.

Design

A double-blind randomized clinical trial

Settings and conduct

This study is conducted in the Diabetes Clinic of the Endocrine and Metabolism Center of Tehran University of Medical Sciences. The doctor and the patient do not know whether the prescribed product is a drug or a placebo.

Participants/Inclusion and exclusion criteria

Inclusion criteria 1. Age: thirty to sixty-five years 2. Uncontrolled type 2 diabetes 3. The amount of HbA1c is more than seven and less than eight and a half 4. At least one month has passed since adding the dose of anti-diabetic medicine or prescribing a new anti-diabetic medicine Exclusion criteria: 1- Glomerular filtration rate, less than 60 ml/min 2- Serum albumin, less than 4 grams per deciliter 3- High SGOT and SGPT more than three times the normal level 4- Pregnancy and breastfeeding or intention to become pregnant 5- Taking insulin along with oral diabetes medications

Intervention groups

Intervention group: In addition to the standard treatment of diabetes, one Tabashir capsule (500 mg) three times a day. Control group: In addition to the standard treatment, a placebo of the same weight and with an indistinguishable appearance, one capsule three times a day

Main outcome variables

Two-hour blood glucose and fasting blood glucose levels and HbA1c levels

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20230307057648N1**

Registration date: **2024-01-08, 1402/10/18**

Registration timing: **prospective**

Last update: **2024-01-08, 1402/10/18**

Update count: **0**

Registration date

2024-01-08, 1402/10/18

Registrant information

Name

Mahbubeh Bozorgi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 5521 4060

Email address

mahboubehbozorgi@gmail.com

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2024-02-20, 1402/12/01

Expected recruitment end date

2025-02-19, 1403/12/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effect of traditional Persian diabetes product (Tabashir tablet) on blood glucose level in patients with type 2 diabetes: a double-blind placebo-controlled clinical trial

Public title

Effect of Tabashir tablet in treatment of diabetes

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Uncontrolled type 2 diabetes Age 30-65 years HbA1c greater than 7 and lower than 8.5 Under treatment with oral diabetes medications (one or more drug groups) At least one month after increasing the dose of antidiabetic medicine or prescribing a new antidiabetic medicine

Exclusion criteria:

Glomerular filtration rate, lower than 60 ml per minute Serum albumin, lower than 4 g/dL SGOT and SGPT, three times higher than normal level Pregnancy and breastfeeding or intention to become pregnant Taking insulin along with oral diabetes medications

Age

From **30 years** old to **65 years** old

Gender

Both

Phase

3

Groups that have been masked

- Participant
- Investigator

Sample size

Target sample size: **106**

Randomization (investigator's opinion)

Randomized

Randomization description

Diabetic patients are randomly divided into two groups "control, intervention" after examination and if they meet the criteria to enter the trial. The random block method with blocks of four will be used by using online websites for random allocation. A numerical code is defined for the random sequence, and people receive the numerical code in the same order as they enter and are placed in the corresponding group according to the block

Blinding (investigator's opinion)

Double blinded

Blinding description

Medicine and placebo are prepared with a completely similar appearance. The patient enters the plan with his consent and receiving full explanations, but he does not know whether he has received a drug or a placebo, and the doctor is not aware of whether the product he is giving to the patient is a drug or a placebo.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Research Institute of Endocrine and Metabolism, Tehran university of medical sci

Street address

Tehran, Persian Gulf Highway (Tehran-Qom), Shahed University

City

Tehran

Province

Tehran

Postal code

3319118651

Approval date

2022-06-15, 1401/03/25

Ethics committee reference number

IR.TUMS.EMRI.REC.1401.008

Health conditions studied

1

Description of health condition studied

diabetes

ICD-10 code

E11

ICD-10 code description

Type 2 diabetes mellitus

Primary outcomes

1

Description

blood sugar

Timepoint

Blood sugar measurement at the beginning of the study (before the start of the intervention) and three months after taking the Tabashir capsule

Method of measurement

Blood test

Secondary outcomes

1

Description

Lipid profile

Timepoint

At the beginning and end of three months of study

Method of measurement

Blood test

Intervention groups

1

Description

Intervention group: One 500 mg Tabashir capsule three times a day. . Formulation (in w/w) Tabashir powder 13.2, licorice root solid extract 13.2, lettuce seed 26.5, purslane seed 20, Armenian bole 2.6, rose bud powder without sepals 6.6, Coriander leaf and stem powder 6.6, acacia extract powder 2.6, gum arabic powder 2.6, white sandal solid powder 2.6, gelnar solid powder 2.6, camphor solid powder 0.6

Category

Treatment - Drugs

2

Description

Control group: Receiving 500 mg placebo capsules containing starch

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Superspecialized Diabetes Clinic

Full name of responsible person

Mahbubeh Bozorgi

Street address

No. 4, Ostad Nejatollahi St., Tehran - Elkhebal St.

City

Tehran

Province

Tehran

Postal code

1411713139

Phone

+98 21 8880 8005

Email

mahboubehbozorgi@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Ms. Salimi

Street address

Endocrine and Metabolism Research Institute, next to Dr. Shariati Hospital, Jalal Al Ahmad Highway, Tehran

City

Tehran

Province

Tehran

Postal code

1411713139

Phone

+98 21 8863 1298

Email

emrc@tums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

No

Title of funding source

Valiasr traditional medicine clinic (Dr.kordafshar clinic)

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Other

Person responsible for general inquiries

Contact

Name of organization / entity

Shahed University

Full name of responsible person

Mahbubeh Bozorgi

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Traditional Medicine

Street address

Khalij Fars Expressway, Shahed university

City

Tehran

Province

Tehran

Postal code

3319118651

Phone

+98 21 5521 4060

Fax

Email

mahboubehbozorgi@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Shahed University

Full name of responsible person

Mahbubeh Bozorgi

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Traditional Medicine

Street address

Khalij Fars Expressway, Shahed university

City

Tehran

Province

Tehran

Postal code

3319118651

Phone

+98 21 5521 4060

Fax**Email**

mahboubbehbozorgi@gmail.com

Person responsible for updating data**Contact****Name of organization / entity**

Shahed University

Full name of responsible person

Mahbubeh Bozorgi

Position

Associate professor

Latest degree

Ph.D.

Other areas of specialty/work

Traditional Medicine

Street address

Khalij Fars Expressway, Shahed university

City

Tehran

Province

Tehran

Postal code

3319118651

Phone

+98 21 5521 4060

Fax**Email**

mahboubbehbozorgi@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Confidentiality principles will be observed in publishing patient information. The method and results section will be mentioned in full in the article that will be written from this research.

When the data will become available and for how long

Information will be available from the time the article is published.

To whom data/document is available

Method information and results are mentioned in the article and will be available to the public

Under which criteria data/document could be used

The information that is not published in the article will be provided to other researchers, if necessary, while maintaining privacy and confidentiality

From where data/document is obtainable

The information published in the article will be available to the public. To obtain other documents, you should contact the project manager.

What processes are involved for a request to access data/document

Contact with the project manager is done via email. Then, the request is reviewed by the project manager and, if necessary, by the ethics committee, so that if there is no ethical problem, it is possible to access the documents.

Comments